Premium
Prostate Apoptosis Response 4 Gene Is Not Associated with Methamphetamine‐Use Disorder in the Japanese Population
Author(s) -
Kishi Taro,
Ikeda Masashi,
Kitajima Tsuyoshi,
Yamanouchi Yoshio,
Kinoshita Yoko,
Kawashima Kunihiro,
Inada Toshiya,
Harano Mutsuo,
Komiyama Tokutaro,
Hori Toru,
Yamada Mitsuhiko,
Iyo Masaomi,
Sora Ichiro,
Sekine Yoshimoto,
Ozaki Norio,
Ujike Hiroshi,
Iwata Nakao
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1432.024
Subject(s) - methamphetamine , apoptosis , gene , prostate , population , medicine , genetics , biology , pharmacology , environmental health , cancer
Abnormal intracellular signaling molecules in dopamine signal transduction are thought to be associated with the pathophysiology of methamphetamine (METH)‐use disorder. A recent study reported that a new intracellular protein, prostate apoptosis response 4 (Par‐4), plays a critical role in dopamine 2 receptor signaling. We therefore analyzed the association between the Par‐4 gene (PAWR) and METH‐use disorder in a Japanese population (191 patients with METH‐use disorder and 466 healthy controls). Using the recommended “gene‐based” association analysis, we selected five tagging SNPs in PAWR from the HapMap database. No significant allele/genotype‐wise or haplotype‐wise association was found between PAWR and METH‐use disorder. These results suggest that PAWR does not play a major role in METH‐use disorders in the Japanese population.